Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.25
-2.7 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,065.00
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020 / 07:20PM GMT
Release Date Price:
$131.28
(+0.59%)
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
Hey, everybody. It's Alethia Young. I cover large cap, small, mid-cap biotech here at Cantor. Happy to have Alnylam Pharmaceuticals here with me. I have Jeff Poulton, who's the CFO of the company, and we'll do a fireside chat for 30 minutes. And we're going to just dive right on then since you guys have a lot of stuff going on.
Questions & Answers
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
I guess just one, which is a common question that's popped up, is just you have some commercial products. And just talk a little bit about the COVID impact on the business for ONPATTRO and GIVLAARI. And maybe some of the similarities and differences of COVID impacts between those 2 programs and different indications.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO
Sure. Welcome. It's nice to be here. Let me remind you, first, what we shared on our Q1 call, which
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot